Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Inhibikase Therapeutics Inc IKT

Healthcare Biotechnology
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease... see more

Recent & Breaking News (NDAQ:IKT)

Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs

PR Newswire November 7, 2022

Inhibikase Therapeutics to Present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets Conference

PR Newswire October 12, 2022

Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference

PR Newswire September 21, 2022

Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress

PR Newswire September 15, 2022

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

PR Newswire September 8, 2022

Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors

PR Newswire September 1, 2022

Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

PR Newswire August 26, 2022

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease

PR Newswire August 23, 2022

Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity

PR Newswire August 12, 2022

Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022

PR Newswire August 8, 2022

Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review

PR Newswire June 13, 2022

Inhibikase Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity

PR Newswire May 16, 2022

Inhibikase Therapeutics to Participate at the H.C. Wainwright Global Investment Conference

PR Newswire May 10, 2022

Inhibikase Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022

PR Newswire May 9, 2022

Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference

PR Newswire April 21, 2022

Inhibikase Therapeutics to Host Virtual KOL Investor Event on April 20, 2022

PR Newswire April 6, 2022

Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity

PR Newswire March 31, 2022

Inhibikase Therapeutics to Participate in the Next Generation Kinase Inhibitors Summit

PR Newswire March 28, 2022

Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022

PR Newswire March 25, 2022

Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference

PR Newswire March 23, 2022